Corcept Therapeutics Company Profile (NASDAQ:CORT)

About Corcept Therapeutics

Corcept Therapeutics logoCorcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company's focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). It has also discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. It has begun pre-clinical and clinical development of its lead compounds from these series.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: CORT
  • CUSIP: 21835210
Key Metrics:
  • Previous Close: $6.92
  • 50 Day Moving Average: $6.36
  • 200 Day Moving Average: $5.69
  • 52-Week Range: $3.22 - $7.18
  • Trailing P/E Ratio: 768.89
  • Foreward P/E Ratio: 30.09
  • P/E Growth: -1.55
  • Market Cap: $765.31M
  • Outstanding Shares: 110,594,000
  • Beta: 1.41
  • Net Margins: 2.06%
  • Return on Equity: 19.40%
  • Return on Assets: 7.18%
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 2.00%
  • Quick Ratio: 1.92%
Additional Links:
Companies Related to Corcept Therapeutics:

Analyst Ratings

Consensus Ratings for Corcept Therapeutics (NASDAQ:CORT) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.67 (54.14% upside)

Analysts' Ratings History for Corcept Therapeutics (NASDAQ:CORT)
DateFirmActionRatingPrice TargetDetails
10/19/2016Piper Jaffray Cos.Set Price TargetBuy$12.00View Rating Details
8/4/2016FBR & CoReiterated RatingBuyView Rating Details
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$8.00View Rating Details
(Data available from 10/27/2014 forward)


Earnings History for Corcept Therapeutics (NASDAQ:CORT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016Q316$0.01$21.24 millionN/AView Earnings Details
8/2/2016Q216$0.01$0.03$18.36 million$19.70 millionViewN/AView Earnings Details
5/3/2016Q116$0.01$0.02$16.32 million$16.10 millionViewN/AView Earnings Details
1/28/2016Q415($0.02)$0.01$15.50 million$15.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.02)($0.01)$13.90 million$13.30 millionViewN/AView Earnings Details
8/5/2015Q215($0.04)($0.02)$11.67 million$11.96 millionViewN/AView Earnings Details
5/7/2015Q115($0.04)($0.05)$10.50 million$10.10 millionViewN/AView Earnings Details
3/4/2015Q414($0.06)($0.02)$9.10 million$9.01 millionViewN/AView Earnings Details
11/4/2014Q214($0.07)($0.06)$7.62 million$7.28 millionViewN/AView Earnings Details
8/5/2014Q2($0.10)($0.05)$6.00 million$5.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.09)($0.11)$5.01 million$4.41 millionViewN/AView Earnings Details
3/5/2014Q413($0.10)($0.11)$4.01 million$4.10 millionViewN/AView Earnings Details
1/30/2014Q4($0.12)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$2.70 million$2.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.10)$2.72 million$1.90 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$2.48 million$1.72 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.09)($0.09)$1.50 million$1.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Corcept Therapeutics (NASDAQ:CORT)
Current Year EPS Consensus Estimate: $0.04 EPS
Next Year EPS Consensus Estimate: $0.23 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.01$0.01$0.01
Q2 20161$0.02$0.02$0.02
Q3 20161$0.03$0.03$0.03
Q4 20161$0.04$0.04$0.04
(Data provided by Zacks Investment Research)


Dividend History for Corcept Therapeutics (NASDAQ:CORT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Corcept Therapeutics (NASDAQ:CORT)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 41.33%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2016G Leonard Baker JrDirectorBuy100,000$4.88$488,000.00View SEC Filing  
1/6/2016James N WilsonDirectorSell1,188$4.90$5,821.20View SEC Filing  
12/10/2015Daniel BradburyDirectorSell20,000$4.85$97,000.00View SEC Filing  
11/24/2015Daniel BradburyDirectorSell40,000$5.00$200,000.00View SEC Filing  
11/12/2015James N WilsonDirectorSell20,000$4.90$98,000.00View SEC Filing  
11/2/2015Steven LoVPSell12,500$4.00$50,000.00View SEC Filing  
10/13/2015Steven LoVPSell53,033$3.82$202,586.06View SEC Filing  
10/7/2015Steven LoVPSell5,300$4.00$21,200.00View SEC Filing  
10/6/2015Steven LoVPSell50,000$3.76$188,000.00View SEC Filing  
9/16/2015Daniel BradburyDirectorSell20,000$4.96$99,200.00View SEC Filing  
9/1/2015James N WilsonDirectorSell10,000$4.90$49,000.00View SEC Filing  
8/27/2015Daniel BradburyDirectorSell20,000$4.76$95,200.00View SEC Filing  
7/21/2015Daniel BradburyDirectorSell10,000$4.98$49,800.00View SEC Filing  
7/20/2015Daniel BradburyDirectorSell10,000$5.32$53,200.00View SEC Filing  
7/8/2015David L MahoneyDirectorSell33,828$5.74$194,172.72View SEC Filing  
7/1/2015James N WilsonDirectorSell10,000$6.06$60,600.00View SEC Filing  
6/24/2015Daniel BradburyDirectorSell20,000$6.75$135,000.00View SEC Filing  
6/23/2015Daniel BradburyDirectorSell10,000$6.92$69,200.00View SEC Filing  
6/2/2015James N WilsonDirectorSell10,000$6.13$61,300.00View SEC Filing  
3/24/2015Patrick G EnrightDirectorSell1,089,745$5.75$6,266,033.75View SEC Filing  
3/19/2015Joseph C Cook JrDirectorSell77,200$5.22$402,984.00View SEC Filing  
6/11/2014G Leonard Baker JrDirectorBuy103,386$2.32$239,855.52View SEC Filing  
5/13/2014Joseph Cook, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/12/2014Daniel BradburyDirectorBuy138,925$1.80$250,065.00View SEC Filing  
5/9/2014G Leonard Baker, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/2/2014Longitude Venture Partners L.PDirectorSell250,000$4.11$1,027,500.00View SEC Filing  
4/1/2014Patrick EnrightDirectorSell250,000$4.28$1,070,000.00View SEC Filing  
3/7/2014Longitude Venture Partners L.PDirectorSell250,000$4.00$1,000,000.00View SEC Filing  
3/14/2013Joseph L TurnerDirectorBuy10,000$2.01$20,100.00View SEC Filing  
12/5/2012G Leonard Baker JrDirectorBuy87,131$1.46$127,211.26View SEC Filing  
11/23/2012Daniel BradburyDirectorBuy179,000$1.39$248,810.00View SEC Filing  
11/7/2012G Leonard Baker JrDirectorBuy300,000$1.83$549,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Corcept Therapeutics (NASDAQ:CORT)
DateHeadline logoCorcept Therapeutics to Announce Third Quarter 2016 Financial Results and Corporate Update and Host Conference Call (NASDAQ:CORT) - October 26 at 9:29 AM
News IconPiper Jaffray Cos. Reiterates $12.00 Price Target for Corcept Therapeutics Inc. (CORT) - DailyQuint (NASDAQ:CORT) - October 25 at 9:15 AM
News IconForging Higher Over Past 6-Months, Can It Continue For Corcept Therapeutics Incorporated (NASDAQ:CORT) - CSZ News (NASDAQ:CORT) - October 16 at 4:17 PM
News IconWhat is the Street Saying About Corcept Therapeutics Incorporated (NASDAQ:CORT)? - CSZ News (NASDAQ:CORT) - October 14 at 4:13 PM
News IconSwiss National Bank Purchases 17700 Shares of Corcept Therapeutics Inc. (CORT) - DailyQuint (NASDAQ:CORT) - October 12 at 4:39 PM logoCorcept Therapeutics: Cushing's Syndrome Is Just The Beginning - Seeking Alpha (NASDAQ:CORT) - October 11 at 4:28 PM logoCorcept Therapeutics Incorporated (CORT) (NASDAQ:CORT) - October 5 at 9:33 AM
News IconCorcept Therapeutics Incorporated (CORT) Updated Broker Price Targets - The De Soto Edge (NASDAQ:CORT) - October 3 at 4:13 PM logoTop 3 Growth Stocks Under $10 (NASDAQ:CORT) - September 29 at 4:16 PM logoGlaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S. - Nasdaq (NASDAQ:CORT) - September 27 at 8:55 AM logoCorcept Therapeutics Incorporated (NASDAQ:CORT)'s Expectation Of $1127.195 In Sales - Investor Newswire (NASDAQ:CORT) - September 25 at 3:58 PM logoETF’s with exposure to Corcept Therapeutics, Inc. : September 22, 2016 (NASDAQ:CORT) - September 22 at 4:30 PM logoAdamas (ADMS) Parkinson's Disease Drug Positive in Phase III - Yahoo Finance (NASDAQ:CORT) - September 22 at 9:55 AM
News IconEarnings Take Center Stage; Analysts Weighing in on Corcept Therapeutics Incorporated (NASDAQ:CORT) - Frisco Fastball (NASDAQ:CORT) - September 22 at 9:55 AM
News IconFBR & Co. Reaffirms Outperform Rating for Corcept Therapeutics (CORT) - Petro Global News 24 (NASDAQ:CORT) - September 22 at 9:55 AM logoHere are 2 Momentous Healthcare Stocks to Buy Now (NASDAQ:CORT) - September 21 at 4:55 PM logoExpected For Corcept Therapeutics Incorporated (NASDAQ:CORT) Sales Of $1127.195 - Investor Newswire (NASDAQ:CORT) - September 18 at 4:16 PM
News IconCorcept Therapeutics Incorporated (NASDAQ:CORT) Shorts Decreased by 1.15% After Short Covering - Post News (NASDAQ:CORT) - September 18 at 9:02 AM
News IconAnalysts Place Corcept Therapeutics Incorporated (NASDAQ:CORT) Under the Lens of the Microscope - Post News (NASDAQ:CORT) - September 15 at 4:45 PM
News IconWhat are Brokerage Firms Saying About Corcept Therapeutics Incorporated (NASDAQ:CORT)? - Frisco Fastball (NASDAQ:CORT) - September 14 at 4:26 PM logoNivalis Therapeutics (NVLS) Catches Eye: Stock Jumps 5.8% (NASDAQ:CORT) - September 14 at 8:38 AM logoAuris (EARS) Advances on Sudden Deafness Study, Stock Up (NASDAQ:CORT) - September 12 at 9:11 AM
News IconShares Lower Over the Past Quarter: Corcept Therapeutics Incorporated (NASDAQ:CORT) - Post News (NASDAQ:CORT) - September 11 at 8:54 AM logoCorcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : September 9, 2016 (NASDAQ:CORT) - September 9 at 4:15 PM
News IconPlacing Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Under the Microscope - Post News (NASDAQ:CORT) - September 8 at 8:05 AM
News IconCan Earnings Grow for Corcept Therapeutics Incorporated (NASDAQ:CORT)? - Frisco Fastball (NASDAQ:CORT) - September 6 at 9:15 AM logoBet on These 5 Profitable Stocks for Big Returns (NASDAQ:CORT) - September 2 at 9:11 AM logoMallinckrodt to Divest Nuclear Imaging Business for $690M (NASDAQ:CORT) - August 25 at 9:20 AM
News IconJ&J (JNJ) Seeks EU Approval for Darzalex's Expanded Use - Yahoo Sports (NASDAQ:CORT) - August 24 at 4:21 PM logoJ&J (JNJ) Seeks EU Approval for Darzalex's Expanded Use (NASDAQ:CORT) - August 24 at 9:58 AM logoETF’s with exposure to Corcept Therapeutics, Inc. : August 22, 2016 (NASDAQ:CORT) - August 22 at 4:26 PM logoHorizon (HZNP) Rayos Receives USPTO Notice of Allowance (NASDAQ:CORT) - August 19 at 10:41 AM logoCorcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : August 19, 2016 (NASDAQ:CORT) - August 19 at 10:41 AM logoOncoGenex Down on Poor Phase III Data on Lead Cancer Drug (NASDAQ:CORT) - August 17 at 4:32 PM logoCorcept Therapeutics Incorporated (NASDAQ:CORT) Ratings in Focus - Stocks Daily (NASDAQ:CORT) - August 17 at 10:25 AM logoEndo (ENDP) Withdraws Label Expansion Filing for Opana ER (NASDAQ:CORT) - August 16 at 4:26 PM logoMallinckrodt (MNK) to Buy Stratatech for Undisclosed Value (NASDAQ:CORT) - August 12 at 4:23 PM logoETF’s with exposure to Corcept Therapeutics, Inc. : August 11, 2016 (NASDAQ:CORT) - August 11 at 4:28 PM logoPerrigo (PRGO) Misses Q2 Earnings Estimates, Cuts '16 View (NASDAQ:CORT) - August 10 at 10:32 PM logoStocks within Analysts Spotlight: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , Corcept Therapeutics ... - Street Updates (NASDAQ:CORT) - August 10 at 8:01 AM logoInovio (INO) Q2 Loss in Line with Estimates, Revenues Top (NASDAQ:CORT) - August 9 at 11:13 AM logoWhy Corcept Therapeutics (CORT) Could Be a Potential Winner (NASDAQ:CORT) - August 9 at 11:13 AM logoNovo Nordisk (NVO) Beats Q2 Earnings, Revenues Up Y/Y (NASDAQ:CORT) - August 8 at 9:12 AM logoEgalet (EGLT) Catches Eye: Stock Adds 6.8% in Session (NASDAQ:CORT) - August 8 at 9:12 AM logoAVEO (AVEO) Reports a Wider Loss in Q2, Tivozanib in Focus (NASDAQ:CORT) - August 5 at 11:29 AM logo5 Liquid Stocks for a Steady Flow of High Returns (NASDAQ:CORT) - August 5 at 11:29 AM logoCorcept Therapeutics Incorporated (CORT) Jumps 5.77% on August 03 - (NASDAQ:CORT) - August 4 at 10:02 PM logoEdited Transcript of CORT earnings conference call or presentation 2-Aug-16 9:00pm GMT (NASDAQ:CORT) - August 3 at 10:59 AM logoCORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:CORT) - August 3 at 10:59 AM logoCorcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : August 3, 2016 (NASDAQ:CORT) - August 3 at 10:59 AM


Corcept Therapeutics (NASDAQ:CORT) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by Staff